Skip to content
Menu

HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $4 to $2.

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $4 to $2.

Read at benzinga.com

← All stock news